about
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activationPEGylated Adenoviruses: From Mice to MonkeysSite-Specific PEGylation of Therapeutic ProteinsNew Therapeutic Approaches in Polycythemia VeraFuture of coagulation factor replacement therapySite-specific functionalization of proteins and their applications to therapeutic antibodiesAutomated solid-phase peptide synthesis to obtain therapeutic peptidesUse of the tumor necrosis factor-blockers for Crohn's diseasePEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injuryA better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycolXTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based CytostaticPEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated AttributesPEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinityAdvanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical productsDirect quantitative 13 C-filtered 1 H magnetic resonance imaging of PEGylated biomacromolecules in vivo.Emerging PEGylated drugs.Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression.Novel pegylated interferon-β as strong suppressor of the malignant ascites in a peritoneal metastasis model of human cancer.Molecularly defined antibody conjugation through a selenocysteine interface.Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity.Identification and characterization of Nanobodies targeting the EphA4 receptor.Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.Avidity-controlled delivery of angiogenic peptides from injectable molecular-recognition hydrogelsAcceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats.Ocular delivery of macromoleculesEncapsidated atom-transfer radical polymerization in Qβ virus-like nanoparticlesDelivery and therapeutic potential of human granzyme B.Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.Genetic PEGylationGlyco-modification of protein with O-cyanate chain-end functionalized glycopolymer via isourea bond formationOptimal structural design of mannosylated nanocarriers for macrophage targeting.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogelsAdditive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymesSpecies differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusPrevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.
P2860
Q24324563-0B88F09A-C632-49A7-B367-752688BD1EC8Q24635276-615EF6C3-BC7D-411C-808F-3D2E8E763D4EQ26777819-C5BCF567-61BA-48A2-B55D-A914EF6398E4Q26795677-9156ED42-E92F-4818-B64D-EDC1E1A886BEQ26820824-21E57FB4-9099-4668-96C1-38D033D02AB7Q26830699-EB6D605C-7025-4C99-999A-53E61765A48BQ27001623-712DE83C-5725-4A1D-B49B-E66727402576Q27030762-9C478BF4-282B-4156-B39D-822B0E9F5808Q27691352-FF3FD50A-3A69-4430-80A4-25B0FBF1F2D2Q28066686-A6FD3141-12A7-4412-80AB-139589768892Q28478454-E9D2D4BF-7B1D-41A2-8B48-62E931759AA8Q28550226-9E48A88E-C173-415E-8D1C-B5F64C3E8A44Q28552198-F956EB49-5720-4D26-9469-3C04C6429245Q28741459-DFEE61A2-CC9A-479A-814D-8EAAAC9377DFQ30402317-E8C7CEDF-8E87-42A3-98AD-B8E1270AB258Q31077545-1EFF76C7-51A2-4A4A-832D-D3CDE844F401Q33447691-811F6E64-57D0-4866-973C-D93140BAFE59Q33588194-8FC61BC4-291C-432A-9A15-9BAEDBA8D144Q33607438-8AB43E12-3F3B-4FB5-80C8-56311EE8A9F5Q33675575-B3E9CA47-71E1-43AA-B40A-ADF2AA692A66Q33684631-FF02C282-1C15-447E-801D-F3BF8AAF0F88Q33712928-92DE4C70-520C-4C57-9697-D634430E2CBFQ33763719-EF1F9975-3F91-4691-8D1B-98777B9FA50AQ33882055-42B16620-5E19-401E-8349-E591D9A109F7Q33944531-D46CC2C8-02FD-4F4B-9F3E-C8AECD8B71F0Q34063536-B910E6BE-98FE-45E8-87A7-241A1DEDA155Q34076711-584BFAC8-194B-4871-AAFE-6C0BD208A50BQ34079676-699F15CF-7E20-475D-87B4-8BD1C8C3064DQ34104230-A2028A38-C496-4FA0-AAE6-719023FE3799Q34120062-A3E29B52-FC29-4845-97AE-D02A5040801EQ34291783-773ADBEE-0A85-47A2-9C30-545C50B67EECQ34474297-1A10CF0D-665A-42BF-BA79-8242A1FA6626Q34535084-24954C44-DBD9-4A42-9F6D-38F7C027D9D0Q34623115-2D1BB096-2A41-4427-92B9-EB70C40670D0Q34626479-D71245DC-D0D9-4DD2-9CB7-A3D9EFB1DD7AQ34628978-7D34FC18-1BD5-4388-9F2C-0AAB27D109D2Q34672618-30CE0271-8B77-4196-964A-984FB7EB84EFQ34938414-8B156459-1D56-4472-953B-32DD80EF5B31Q34975214-ACE710D2-3E07-4236-B9EA-A3949AFFC300Q35062556-55DD6A9F-57BC-4660-A9DF-747BF56ECC7E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
gotara zanistî
@ku-latn
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
The impact of PEGylation on biological therapies.
@en
The impact of PEGylation on biological therapies.
@nl
type
label
The impact of PEGylation on biological therapies.
@en
The impact of PEGylation on biological therapies.
@nl
prefLabel
The impact of PEGylation on biological therapies.
@en
The impact of PEGylation on biological therapies.
@nl
P1433
P1476
The impact of PEGylation on biological therapies.
@en
P2093
Francesco M Veronese
P304
P356
10.2165/00063030-200822050-00004
P577
2008-01-01T00:00:00Z
P6179
1027128924